Turn newly discovered natural products
into assets worth developing.

Assess natural scaffolds, optimization handles and differentiation from existing series. Natural origin alone does not establish novelty.

Define the disease and mechanism question, then assess phenotypes, target engagement and exposure. Docking scores alone do not establish pharmacological activity.

Organize structure confirmation, stereochemistry, purity, provenance and known analogues to assess novelty and optimization potential.

Connect functional assays, orthogonal validation, target engagement and disease models. Examine assay interference, nonspecific effects and counterevidence.

Prioritize decision-changing studies around exposure, selectivity, solubility, metabolism and early safety.

Assess resupply, synthesis or semisynthesis, process starting points and critical dependencies so findings can be reproduced and expanded.

Map source and usage rights, inventorship, patent-space leads, partnership rights and value milestones. Formal patentability and freedom-to-operate require specialist diligence.